Sigma Planning Corp Sells 7,783 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Sigma Planning Corp reduced its Gilead Sciences stake by 27.7% in the first quarter, selling 7,783 shares and leaving it with 20,278 shares valued at about $2.83 million.
• Gilead reported strong quarterly results, with EPS of $2.03 beating estimates and revenue of $6.96 billion topping expectations, while revenue rose 4.4% year over year.
• The company continues to return cash to shareholders, paying a quarterly dividend of $0.82 per share, or $3.28 annually, for a yield of about 2.4%.

Sigma Planning Corp lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,278 shares of the biopharmaceutical company's stock after selling 7,783 shares during the period. Sigma Planning Corp's holdings in Gilead Sciences were worth $2,826,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its position in Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares during the last quarter. State Street Corp grew its holdings in shares of Gilead Sciences by 1.9% during the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company's stock valued at $7,393,921,000 after buying an additional 1,151,213 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Gilead Sciences by 4.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company's stock valued at $3,399,734,000 after buying an additional 1,195,269 shares during the last quarter. Bank of America Corp DE increased its position in shares of Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company's stock valued at $2,837,948,000 after acquiring an additional 3,046,688 shares in the last quarter. Finally, Norges Bank purchased a new position in Gilead Sciences in the 4th quarter worth approximately $2,617,152,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

GILD stock opened at $136.30 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. Gilead Sciences, Inc. has a 1 year low of $107.75 and a 1 year high of $157.29. The company has a market cap of $169.23 billion, a P/E ratio of 18.57 and a beta of 0.32. The stock's fifty day moving average price is $129.67 and its 200-day moving average price is $135.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts' consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analysts' expectations of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences's revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.77 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date was Monday, June 15th. Gilead Sciences's dividend payout ratio is 44.69%.

Wall Street Analyst Weigh In

GILD has been the topic of several recent analyst reports. Truist Financial cut their target price on Gilead Sciences from $157.00 to $156.00 and set a "buy" rating on the stock in a research note on Tuesday, July 7th. Leerink Partners lowered their price target on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. The Goldman Sachs Group increased their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a "neutral" rating in a research report on Friday, April 17th. Maxim Group upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price objective for the company in a report on Wednesday, May 20th. Finally, Daiwa Securities Group decreased their target price on Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating for the company in a research report on Tuesday, May 19th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $159.04.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 15,000 shares of the business's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the sale, the chief executive officer directly owned 607,133 shares of the company's stock, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 77,000 shares of company stock valued at $9,978,740. 0.30% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.